Evidence map›Paper›PMID 41940168›Full record

ReviewJournal of pharmaceutical analysis2026

Mechanisms and therapeutic potential of YTHDF readers: Linking epitranscriptomics to cancer.

Na Deng, Qiang Sun, Shuying Wang, Shiheng Jia, Chen Zheng, Fanglin Wang, Shuang Ma, Heng Zhou, Weiwei Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Na DengKey Laboratory of Molecular Pathology and Epidemiology of Gastric Cancer in Liaoning Education Department, The First Hospital of China Medical University, Shenyang, 110001, China.
Qiang SunDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 110001, Shenyang, China.
Shuying WangDepartment of Anesthesiology, The First Hospital of China Medical University, Shenyang, 110001, China.
Shiheng JiaDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 110001, Shenyang, China.
Chen ZhengDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 110001, Shenyang, China.
Fanglin WangDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 110001, Shenyang, China.
Shuang MaDepartment of Clinical Nutrition, The First Hospital of China Medical University, Shenyang, 110001, China.
Heng ZhouKey Laboratory of Molecular Pathology and Epidemiology of Gastric Cancer in Liaoning Education Department, The First Hospital of China Medical University, Shenyang, 110001, China.
Weiwei LiuDepartment of Anesthesiology, The First Hospital of China Medical University, Shenyang, 110001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

YT521-B homology domain-containing family paralogs (YTHDFs), as RNA epigenetic modification effector proteins, fully or partially participate in N

Indexed as

CancerCancer therapyReaderRNA epigenetic modificationTherapy resistanceYTHDFs

Identifiers

PMID41940168
PMCPMC13049655

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.